We, therefore, infected animals with a high viral dose (105TCID50) and tested three anti-IFNAR1 mAb dosing regimens: 0.1 mg or 1 mg administered 48 h before infection, and 1 mg administered 48 h before infection followed by an additional 0.5 mg dose at 1 dpi to ensure continued blocking of IFNAR1. Here, IFNAR1 is linked to infection.